Zoetis (ZTS) Could Be 13% Below Fair Value After FDA Approval

Simply Wall St.10-26

AdvertisementFDA approval for Convenia RTU puts Zoetis in focus Zoetis (ZTS) received FDA approval for Convenia RTU for Dogs, a single-dose injectable antibiotic for bacterial skin infections, ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2678199179?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/215548781-card/1789129645905","is_english":true,"pubTime":"2026-10-26 21:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2678199179","market":"hk","top_or_hot":-1,"title":"Zoetis (ZTS) Could Be 13% Below Fair Value After FDA Approval","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementFDA approval for Convenia RTU puts Zoetis in focus Zoetis (ZTS) received FDA approval for Convenia RTU for Dogs, a single-dose injectable antibiotic for bacterial skin infections, ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-zts/zoetis/news/zoetis-zts-could-be-13-below-fair-value-after-fda-approval\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zoetis (ZTS) Could Be 13% Below Fair Value After FDA Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZoetis (ZTS) Could Be 13% Below Fair Value After FDA Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-10-26 21:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-zts/zoetis/news/zoetis-zts-could-be-13-below-fair-value-after-fda-approval><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementFDA approval for Convenia RTU puts Zoetis in focus Zoetis (ZTS) received FDA approval for Convenia RTU for Dogs, a single-dose injectable antibiotic for bacterial skin infections, ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-zts/zoetis/news/zoetis-zts-could-be-13-below-fair-value-after-fda-approval\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ZTS","symbol_name":"Zoetis Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-zts/zoetis/news/zoetis-zts-could-be-13-below-fair-value-after-fda-approval","article_id":"2678199179","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/215548781-card/1789129645905"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-zts/zoetis/news/zoetis-zts-could-be-13-below-fair-value-after-fda-approval","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2678199179","pubTimestamp":1793021088,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"FDA approval for Convenia RTU puts Zoetis in focus\nZoetis (ZTS) received FDA approval for Convenia RTU for Dogs, a single-dose injectable antibiotic for bacterial skin infections, expanding its established Convenia franchise in companion animal medicine.\nThe FDA green light lands at a tricky moment for Zoetis. The shares trade at US$81.03 after a 30 day share price return of 14.05%. However, the year to date share price return is down 35.65% and the 5 year total shareholder return has...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"ZTS":"Zoetis Inc.","LU2028103732.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AMG\" (USD) INC","LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","LU0158827781.USD":" ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (USD) ACC","LU1941712264.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"A\" (USD) INC","LU0345774631.USD":"NINETY ONE GSF AMERICAN FRANCHISE \"A\" (USD) INC","LU2308191902.HKD":"BNP PARIBAS ECOSYSTEM RESTORATION \"CLASSIC\" (HKD) ACC","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","LU0079474960.USD":"联博美国增长基金A","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","LU0471298694.HKD":"BGF NUTRITION \"A2\" (HKD) ACC","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","LU0471298777.SGD":"Blackrock Nutrition A2 SGD-H","LU0107464264.USD":"abrdn SICAV I - GLOBAL INNOVATION EQUITY \"A\" (USD) ACC","LU0345774391.USD":"NINETY ONE GSF AMERICAN FRANCHISE \"A\" (USD) ACC","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","LU1721429741.USD":"BNP PARIBAS SMART FOOD \"CRH\" (USD) INC","LU1721429402.USD":"BNP PARIBAS SMART FOOD \"C\" (USD) ACC","LU1236620750.USD":"HSBC GIF GLOBAL SUSTAINABLE LONG TERM DIVIDEND \"AM2\" (USD) INC","LABU":"三倍做多标普生物-Direxion","LU2271345857.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (HKD) ACC","LU2360106947.USD":"BGF NUTRITION \"A4\" (USD) INC","LU1236620834.HKD":"HSBC GIF GLOBAL SUSTAINABLE LONG TERM DIVIDEND \"AM2\" (HKD) INC","PAWZ":"ProShares Pet Care ETF","IE00B19Z9505.USD":"美盛-美国大盘成长股A Acc","LU0058720904.USD":"联博国际健康护理基金A","LU2111349929.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (HKD) INC","LU0385154629.USD":"贝莱德营养科学基金A2","BK4588":"碎股","LU1941712348.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"AT\" (USD) ACC","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","BK4007":"制药"},"translate_title":"FDA 批准后，硕腾 (ZTS) 可能比公允价值低 13%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZTS":1.5,"LABU":1.5,"PAWZ":0.6},"content_text":"AdvertisementFDA approval for Convenia RTU puts Zoetis in focus Zoetis (ZTS) received FDA approval for Convenia RTU for Dogs, a single-dose injectable antibiotic for bacterial skin infections, expanding its established Convenia franchise in companion animal medicine. The FDA green light lands at a tricky moment for Zoetis. The shares trade at US$81.03 after a 30 day share price return of 14.05%. However, the year to date share price return is down 35.65% and the 5 year total shareholder return has declined 59.92%. This signals recent momentum picking up after a much weaker long run and suggests investors may be reassessing both growth prospects and risk around the business. Scan for other animal health and veterinary stocks showing fresh momentum and resilient fundamentals with our curated 28 high quality undervalued stocks alongside Zoetis after this FDA approval. Zoetis now trades at US$81.03, with analyst targets and intrinsic value estimates pointing to a wide gap. After this sharp rebound, what is a reasonable fair value range for the stock today? Most Popular Narrative: 12.8% Undervalued Against the last close at $81.03, the most widely followed narrative on Zoetis pegs fair value around $92.92, implying a material valuation gap that investors are now weighing against slow but positive earnings trends and the fresh FDA approval for Convenia RTU.  World's leading animal pharma company at 13x PE with 9% EPS growth. Occasionally something crosses my eye which screens well, but after some work is done it isn’t interesting enough to warrant writing about it as a paid article. Zoetis is one such stock. There are hints of genuine value in the position, but I figured there wouldn’t be enough people interested in their single-digit growth. I already finished the analysis halfway, so I thought I’d share it with those who are interested in it.  Find out how 29 investors see Zoetis as 13% undervalued. According to ValueInvestingSubstack, Zoetis combines a long record of positive earnings progression, including 6.9% annual profit growth over the last five years, with steady revenue expansion and a focused position in companion animals and livestock. That narrative frames the current pricing as a discount to a resilient franchise that reports $9.5b in annual revenue and $2.6b in net income while paying a 2.62% dividend yield. The same analysis flags key tension points for readers to weigh, especially the use of debt funded buybacks, a high overall leverage position and a sharp recent drop in U.S. companion animal revenue that contributed to the share price reset. Earnings are forecast to grow around 2.9% per year and revenue around 2% per year, which is slower than the broader U.S. market, so the valuation story here leans more on quality and cash flow strength than on rapid expansion. Putting those threads together, the Simply Wall St narrative model applies a 7.108% discount rate and arrives at a fair value estimate of $92.92 per share, around 12.8% above the last close. That sits between the intrinsic value range of $190.68 implied by the SWS DCF work and the $93 analyst price target, and it reflects an assessment that Zoetis offers high return on equity and strong profitability, offset by leverage and modest growth expectations. Result: Fair Value of $92.92 (UNDERVALUED) Still, the Zoetis story could be knocked off course if the U.S. companion animal weakness deepens or if debt funded buybacks start to worry lenders. Find out about the key risks to this Zoetis narrative. Next Steps Curious whether Zoetis looks more like a cautious opportunity or a value trap at this stage of the reset in expectations? Act quickly, review both the caution flags and upside drivers, and ground your view in the 4 key rewards and 1 important warning sign. Looking for more investment ideas beyond Zoetis? Do not stop your research with Zoetis. Broaden your watchlist with a few targeted filters that surface specific kinds of opportunities other investors may be overlooking.  Target stability first and hunt for resilient businesses with lower risk profiles by scanning the 30 resilient stocks with low risk scores to help smooth out portfolio swings. Prioritise balance sheet strength and focus on companies with cleaner finances using the list of solid balance sheet and fundamentals (24 results) so you are not caught off guard by hidden leverage. Zoom in on potential future leaders before they hit the mainstream by working through the 21 high quality undiscovered gems while others stay parked in the usual blue chips.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Zoetis might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.1","shortVersion":"4.52.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2678199179","isCrawlerRequest":true}